APO Research
Talk to an analyst

APO RESEARCH · REPORT

Pediatric Preventable Vaccine

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Pediatric Preventable Vaccine Market Outlook and Growth Opportunities 2026

26 December 2025198 pages

Choose your research edition.

Industry ResearchPediatric Preventable Vaccine Industry Research Report 2026131 pages · $2,950 USDIndustry Growth & TrendsGlobal Pediatric Preventable Vaccine Industry Growth and Trends Forecast to 2032112 pages · $3,450 USDMarket StructureGlobal Pediatric Preventable Vaccine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032194 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Pediatric Preventable Vaccine Market Outlook and Growth Opportunities 2026198 pages · $4,250 USDMarket Analysis & ForecastGlobal Pediatric Preventable Vaccine Market Analysis and Forecast 2026-2032198 pages · $4,950 USD

Market perspective

The global Pediatric Preventable Vaccine market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Pediatric Preventable Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Pediatric Preventable Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Pediatric Preventable Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Pediatric Preventable Vaccine market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Pediatric Preventable Vaccine market include Sanofi Pasteur, Johnson & Johnson (Janssen), Pfizer Inc., GlaxoSmithKline plc (GSK), Sinovac Biotech, Sinopharm Group Co.,, Serum Institute of India Pvt., Novavax, Inc. and Moderna, Inc., among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Pediatric Preventable Vaccine market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Pediatric Preventable Vaccine and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Pediatric Preventable Vaccine sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Pediatric Preventable Vaccine market size, projected growth trends, production technologies, key applications, and end-use industries.

Pediatric Preventable Vaccine Segment by Company

Sanofi Pasteur

Johnson & Johnson (Janssen)

Pfizer Inc.

GlaxoSmithKline plc (GSK)

Sinovac Biotech

Sinopharm Group Co.,

Serum Institute of India Pvt.

Novavax, Inc.

Moderna, Inc.

Merck & Co., Inc.

Emergent BioSolutions Inc.

Daiichi Sankyo Company

CSL Limited (Seqirus)

Bharat Biotech International

AstraZeneca plc

Pediatric Preventable Vaccine Segment by Type

Subunit Vaccines

Inactivated Vaccines

Live Vaccines

Viral Vector Vaccines

Mrna Vaccines

Pediatric Preventable Vaccine Segment by Application

Bacterial Diseases

Virus Diseases

Pediatric Preventable Vaccine Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Pediatric Preventable Vaccine status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Pediatric Preventable Vaccine market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Pediatric Preventable Vaccine significant trends, drivers, influence factors in global and regions.

6. To analyze Pediatric Preventable Vaccine competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Pediatric Preventable Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Pediatric Preventable Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Pediatric Preventable Vaccine.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Pediatric Preventable Vaccine market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Pediatric Preventable Vaccine industry.

Chapter 3: Detailed analysis of Pediatric Preventable Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Pediatric Preventable Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Pediatric Preventable Vaccine in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Pediatric Preventable Vaccine Industry Trends Table 2. Pediatric Preventable Vaccine Industry Drivers Table 3. Pediatric Preventable Vaccine Industry Opportunities and Challenges Table 4. Pediatric Preventable Vaccine Industry Restraints Table 5. Global Pediatric Preventable Vaccine Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Pediatric Preventable Vaccine Revenue Share by Company (2021-2026) Table 7. Global Pediatric Preventable Vaccine Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Pediatric Preventable Vaccine Sales Volume Share by Company (2021-2026) Table 9. Global Pediatric Preventable Vaccine Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Pediatric Preventable Vaccine Company Ranking, (2024-2026) & (USD Million) Table 11. Global Pediatric Preventable Vaccine Key Company Manufacturing Base & Headquarters Table 12. Global Pediatric Preventable Vaccine Company, Product Type & Application Table 13. Global Pediatric Preventable Vaccine Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Pediatric Preventable Vaccine by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Subunit Vaccines Table 18. Significant Companies of Inactivated Vaccines Table 19. Significant Companies of Live Vaccines Table 20. Significant Companies of Viral Vector Vaccines Table 21. Significant Companies of Mrna Vaccines Table 22. Global Pediatric Preventable Vaccine Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 23. Global Pediatric Preventable Vaccine Sales Volume by Type (2021-2026) & (K Units) Table 24. Global Pediatric Preventable Vaccine Sales Volume by Type (2027-2032) & (K Units) Table 25. Global Pediatric Preventable Vaccine Sales Volume Share by Type (2021-2026) Table 26. Global Pediatric Preventable Vaccine Sales Volume Share by Type (2027-2032) Table 27. Global Pediatric Preventable Vaccine Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Pediatric Preventable Vaccine Sales Value by Type (2021-2026) & (US$ Million) Table 29. Global Pediatric Preventable Vaccine Sales Value by Type (2027-2032) & (US$ Million) Table 30. Global Pediatric Preventable Vaccine Sales Value Share by Type (2021-2026) Table 31. Global Pediatric Preventable Vaccine Sales Value Share by Type (2027-2032) Table 32. Significant Companies of Bacterial Diseases Table 33. Significant Companies of Virus Diseases Table 34. Global Pediatric Preventable Vaccine Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 35. Global Pediatric Preventable Vaccine Sales Volume by Application (2021-2026) & (K Units) Table 36. Global Pediatric Preventable Vaccine Sales Volume by Application (2027-2032) & (K Units) Table 37. Global Pediatric Preventable Vaccine Sales Volume Share by Application (2021-2026) Table 38. Global Pediatric Preventable Vaccine Sales Volume Share by Application (2027-2032) Table 39. Global Pediatric Preventable Vaccine Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 40. Global Pediatric Preventable Vaccine Sales Value by Application (2021-2026) & (US$ Million) Table 41. Global Pediatric Preventable Vaccine Sales Value by Application (2027-2032) & (US$ Million) Table 42. Global Pediatric Preventable Vaccine Sales Value Share by Application (2021-2026) Table 43. Global Pediatric Preventable Vaccine Sales Value Share by Application (2027-2032) Table 44. Global Pediatric Preventable Vaccine Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 45. Global Pediatric Preventable Vaccine Sales by Region (2021-2026) & (K Units) Table 46. Global Pediatric Preventable Vaccine Sales Market Share by Region (2021-2026) Table 47. Global Pediatric Preventable Vaccine Sales by Region (2027-2032) & (K Units) Table 48. Global Pediatric Preventable Vaccine Sales Market Share by Region (2027-2032) Table 49. Global Pediatric Preventable Vaccine Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 50. Global Pediatric Preventable Vaccine Sales Value by Region (2021-2026) & (US$ Million) Table 51. Global Pediatric Preventable Vaccine Sales Value Share by Region (2021-2026) Table 52. Global Pediatric Preventable Vaccine Sales Value by Region (2027-2032) & (US$ Million) Table 53. Global Pediatric Preventable Vaccine Sales Value Share by Region (2027-2032) Table 54. Global Pediatric Preventable Vaccine Market Average Price (US$/Unit) by Region (2021-2026) Table 55. Global Pediatric Preventable Vaccine Market Average Price (US$/Unit) by Region (2027-2032) Table 56. Global Pediatric Preventable Vaccine Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 57. Global Pediatric Preventable Vaccine Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 58. Global Pediatric Preventable Vaccine Sales by Country (2021-2026) & (K Units) Table 59. Global Pediatric Preventable Vaccine Sales Market Share by Country (2021-2026) Table 60. Global Pediatric Preventable Vaccine Sales by Country (2027-2032) & (K Units) Table 61. Global Pediatric Preventable Vaccine Sales Market Share by Country (2027-2032) Table 62. Global Pediatric Preventable Vaccine Sales Value by Country (2021-2026) & (US$ Million) Table 63. Global Pediatric Preventable Vaccine Sales Value Market Share by Country (2021-2026) Table 64. Global Pediatric Preventable Vaccine Sales Value by Country (2027-2032) & (US$ Million) Table 65. Global Pediatric Preventable Vaccine Sales Value Market Share by Country (2027-2032) Table 66. Sanofi Pasteur Company Information Table 67. Sanofi Pasteur Business Overview Table 68. Sanofi Pasteur Pediatric Preventable Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 69. Sanofi Pasteur Pediatric Preventable Vaccine Product Portfolio Table 70. Sanofi Pasteur Recent Development Table 71. Johnson & Johnson (Janssen) Company Information Table 72. Johnson & Johnson (Janssen) Business Overview Table 73. Johnson & Johnson (Janssen) Pediatric Preventable Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 74. Johnson & Johnson (Janssen) Pediatric Preventable Vaccine Product Portfolio Table 75. Johnson & Johnson (Janssen) Recent Development Table 76. Pfizer Inc. Company Information Table 77. Pfizer Inc. Business Overview Table 78. Pfizer Inc. Pediatric Preventable Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 79. Pfizer Inc. Pediatric Preventable Vaccine Product Portfolio Table 80. Pfizer Inc. Recent Development Table 81. GlaxoSmithKline plc (GSK) Company Information Table 82. GlaxoSmithKline plc (GSK) Business Overview Table 83. GlaxoSmithKline plc (GSK) Pediatric Preventable Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 84. GlaxoSmithKline plc (GSK) Pediatric Preventable Vaccine Product Portfolio Table 85. GlaxoSmithKline plc (GSK) Recent Development Table 86. Sinovac Biotech Company Information Table 87. Sinovac Biotech Business Overview Table 88. Sinovac Biotech Pediatric Preventable Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 89. Sinovac Biotech Pediatric Preventable Vaccine Product Portfolio Table 90. Sinovac Biotech Recent Development Table 91. Sinopharm Group Co., Company Information Table 92. Sinopharm Group Co., Business Overview Table 93. Sinopharm Group Co., Pediatric Preventable Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 94. Sinopharm Group Co., Pediatric Preventable Vaccine Product Portfolio Table 95. Sinopharm Group Co., Recent Development Table 96. Serum Institute of India Pvt. Company Information Table 97. Serum Institute of India Pvt. Business Overview Table 98. Serum Institute of India Pvt. Pediatric Preventable Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 99. Serum Institute of India Pvt. Pediatric Preventable Vaccine Product Portfolio Table 100. Serum Institute of India Pvt. Recent Development Table 101. Novavax, Inc. Company Information Table 102. Novavax, Inc. Business Overview Table 103. Novavax, Inc. Pediatric Preventable Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 104. Novavax, Inc. Pediatric Preventable Vaccine Product Portfolio Table 105. Novavax, Inc. Recent Development Table 106. Moderna, Inc. Company Information Table 107. Moderna, Inc. Business Overview Table 108. Moderna, Inc. Pediatric Preventable Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 109. Moderna, Inc. Pediatric Preventable Vaccine Product Portfolio Table 110. Moderna, Inc. Recent Development Table 111. Merck & Co., Inc. Company Information Table 112. Merck & Co., Inc. Business Overview Table 113. Merck & Co., Inc. Pediatric Preventable Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 114. Merck & Co., Inc. Pediatric Preventable Vaccine Product Portfolio Table 115. Merck & Co., Inc. Recent Development Table 116. Emergent BioSolutions Inc. Company Information Table 117. Emergent BioSolutions Inc. Business Overview Table 118. Emergent BioSolutions Inc. Pediatric Preventable Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 119. Emergent BioSolutions Inc. Pediatric Preventable Vaccine Product Portfolio Table 120. Emergent BioSolutions Inc. Recent Development Table 121. Daiichi Sankyo Company Company Information Table 122. Daiichi Sankyo Company Business Overview Table 123. Daiichi Sankyo Company Pediatric Preventable Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 124. Daiichi Sankyo Company Pediatric Preventable Vaccine Product Portfolio Table 125. Daiichi Sankyo Company Recent Development Table 126. CSL Limited (Seqirus) Company Information Table 127. CSL Limited (Seqirus) Business Overview Table 128. CSL Limited (Seqirus) Pediatric Preventable Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 129. CSL Limited (Seqirus) Pediatric Preventable Vaccine Product Portfolio Table 130. CSL Limited (Seqirus) Recent Development Table 131. Bharat Biotech International Company Information Table 132. Bharat Biotech International Business Overview Table 133. Bharat Biotech International Pediatric Preventable Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 134. Bharat Biotech International Pediatric Preventable Vaccine Product Portfolio Table 135. Bharat Biotech International Recent Development Table 136. AstraZeneca plc Company Information Table 137. AstraZeneca plc Business Overview Table 138. AstraZeneca plc Pediatric Preventable Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 139. AstraZeneca plc Pediatric Preventable Vaccine Product Portfolio Table 140. AstraZeneca plc Recent Development Table 141. Key Raw Materials Table 142. Raw Materials Key Suppliers Table 143. Pediatric Preventable Vaccine Distributors List Table 144. Pediatric Preventable Vaccine Customers List Table 145. Research Programs/Design for This Report Table 146. Authors List of This Report Table 147. Secondary Sources Table 148. Primary Sources List of Figures Figure 1. Pediatric Preventable Vaccine Product Image Figure 2. Global Pediatric Preventable Vaccine Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Pediatric Preventable Vaccine Sales Value (2021-2032) & (US$ Million) Figure 4. Global Pediatric Preventable Vaccine Sales (2021-2032) & (K Units) Figure 5. Global Pediatric Preventable Vaccine Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Pediatric Preventable Vaccine Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Subunit Vaccines Image Figure 10. Inactivated Vaccines Image Figure 11. Live Vaccines Image Figure 12. Viral Vector Vaccines Image Figure 13. Mrna Vaccines Image Figure 14. Global Pediatric Preventable Vaccine Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 15. Global Pediatric Preventable Vaccine Sales Volume Share 2021 VS 2025 VS 2032 Figure 16. Global Pediatric Preventable Vaccine Sales Volume Share by Type (2021-2032) Figure 17. Global Pediatric Preventable Vaccine Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Pediatric Preventable Vaccine Sales Value Share 2021 VS 2025 VS 2032 Figure 19. Global Pediatric Preventable Vaccine Sales Value Share by Type (2021-2032) Figure 20. Bacterial Diseases Image Figure 21. Virus Diseases Image Figure 22. Global Pediatric Preventable Vaccine Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 23. Global Pediatric Preventable Vaccine Sales Volume Share 2021 VS 2025 VS 2032 Figure 24. Global Pediatric Preventable Vaccine Sales Volume Share by Application (2021-2032) Figure 25. Global Pediatric Preventable Vaccine Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 26. Global Pediatric Preventable Vaccine Sales Value Share 2021 VS 2025 VS 2032 Figure 27. Global Pediatric Preventable Vaccine Sales Value Share by Application (2021-2032) Figure 28. Global Pediatric Preventable Vaccine Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 29. Global Pediatric Preventable Vaccine Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 30. Global Pediatric Preventable Vaccine Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 31. Global Pediatric Preventable Vaccine Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 32. North America Pediatric Preventable Vaccine Sales Value (2021-2032) & (US$ Million) Figure 33. North America Pediatric Preventable Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Europe Pediatric Preventable Vaccine Sales Value (2021-2032) & (US$ Million) Figure 35. Europe Pediatric Preventable Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 36. Asia-Pacific Pediatric Preventable Vaccine Sales Value (2021-2032) & (US$ Million) Figure 37. Asia-Pacific Pediatric Preventable Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 38. South America Pediatric Preventable Vaccine Sales Value (2021-2032) & (US$ Million) Figure 39. South America Pediatric Preventable Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 40. Middle East & Africa Pediatric Preventable Vaccine Sales Value (2021-2032) & (US$ Million) Figure 41. Middle East & Africa Pediatric Preventable Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 42. USA Pediatric Preventable Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. USA Pediatric Preventable Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. USA Pediatric Preventable Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. Canada Pediatric Preventable Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. Canada Pediatric Preventable Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. Canada Pediatric Preventable Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Mexico Pediatric Preventable Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Mexico Pediatric Preventable Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Mexico Pediatric Preventable Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Germany Pediatric Preventable Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Germany Pediatric Preventable Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Germany Pediatric Preventable Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. France Pediatric Preventable Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. France Pediatric Preventable Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. France Pediatric Preventable Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. U.K. Pediatric Preventable Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. U.K. Pediatric Preventable Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. U.K. Pediatric Preventable Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Italy Pediatric Preventable Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Italy Pediatric Preventable Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Italy Pediatric Preventable Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Spain Pediatric Preventable Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Spain Pediatric Preventable Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Spain Pediatric Preventable Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Russia Pediatric Preventable Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Russia Pediatric Preventable Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Russia Pediatric Preventable Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Netherlands Pediatric Preventable Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Netherlands Pediatric Preventable Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Netherlands Pediatric Preventable Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. Nordic Countries Pediatric Preventable Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. Nordic Countries Pediatric Preventable Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. Nordic Countries Pediatric Preventable Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. China Pediatric Preventable Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. China Pediatric Preventable Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. China Pediatric Preventable Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Japan Pediatric Preventable Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Japan Pediatric Preventable Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Japan Pediatric Preventable Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. South Korea Pediatric Preventable Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. South Korea Pediatric Preventable Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. South Korea Pediatric Preventable Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. India Pediatric Preventable Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. India Pediatric Preventable Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. India Pediatric Preventable Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Australia Pediatric Preventable Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Australia Pediatric Preventable Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Australia Pediatric Preventable Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Southeast Asia Pediatric Preventable Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Southeast Asia Pediatric Preventable Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Southeast Asia Pediatric Preventable Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Brazil Pediatric Preventable Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Brazil Pediatric Preventable Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Brazil Pediatric Preventable Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Argentina Pediatric Preventable Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Argentina Pediatric Preventable Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Argentina Pediatric Preventable Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Chile Pediatric Preventable Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Chile Pediatric Preventable Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Chile Pediatric Preventable Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Colombia Pediatric Preventable Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Colombia Pediatric Preventable Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Colombia Pediatric Preventable Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Peru Pediatric Preventable Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Peru Pediatric Preventable Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Peru Pediatric Preventable Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Saudi Arabia Pediatric Preventable Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Saudi Arabia Pediatric Preventable Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Saudi Arabia Pediatric Preventable Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Israel Pediatric Preventable Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Israel Arabia Pediatric Preventable Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Israel Arabia Pediatric Preventable Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. UAE Pediatric Preventable Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. UAE Pediatric Preventable Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. UAE Pediatric Preventable Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Turkey Pediatric Preventable Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. Turkey Pediatric Preventable Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. Turkey Pediatric Preventable Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Iran Pediatric Preventable Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Iran Pediatric Preventable Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Iran Pediatric Preventable Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Egypt Pediatric Preventable Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 124. Egypt Pediatric Preventable Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 125. Egypt Pediatric Preventable Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 126. Pediatric Preventable Vaccine Value Chain Figure 127. Manufacturing Cost Structure Figure 128. Pediatric Preventable Vaccine Sales Mode & Process Figure 129. Direct Comparison with Distribution Share Figure 130. Distributors Profiles Figure 131. Years Considered Figure 132. Research Process Figure 133. Key Executives Interviewed

Scope & coverage.

Types
  • Subunit Vaccines
  • Inactivated Vaccines
  • Live Vaccines
  • Viral Vector Vaccines
  • Mrna Vaccines
Applications
  • Bacterial Diseases
  • Virus Diseases
Companies covered
  • Sanofi Pasteur
  • Johnson & Johnson (Janssen)
  • Pfizer Inc.
  • GlaxoSmithKline plc (GSK)
  • Sinovac Biotech
  • Sinopharm Group Co.,
  • Serum Institute of India Pvt.
  • Novavax, Inc.
  • Moderna, Inc.
  • Merck & Co., Inc.
  • Emergent BioSolutions Inc.
  • Daiichi Sankyo Company
  • CSL Limited (Seqirus)
  • Bharat Biotech International
  • AstraZeneca plc

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Pediatric Preventable Vaccine Sales Value (2021-2032)
  4. 1.2.2 Global Pediatric Preventable Vaccine Sales Volume (2021-2032)
  5. 1.2.3 Global Pediatric Preventable Vaccine Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Pediatric Preventable Vaccine Market Dynamics
  1. 2.1 Pediatric Preventable Vaccine Industry Trends
  2. 2.2 Pediatric Preventable Vaccine Industry Drivers
  3. 2.3 Pediatric Preventable Vaccine Industry Opportunities and Challenges
  4. 2.4 Pediatric Preventable Vaccine Industry Restraints
3 Pediatric Preventable Vaccine Market by Company
  1. 3.1 Global Pediatric Preventable Vaccine Company Revenue Ranking in 2025
  2. 3.2 Global Pediatric Preventable Vaccine Revenue by Company (2021-2026)
  3. 3.3 Global Pediatric Preventable Vaccine Sales Volume by Company (2021-2026)
  4. 3.4 Global Pediatric Preventable Vaccine Average Price by Company (2021-2026)
  5. 3.5 Global Pediatric Preventable Vaccine Company Ranking (2024-2026)
  6. 3.6 Global Pediatric Preventable Vaccine Company Manufacturing Base and Headquarters
  7. 3.7 Global Pediatric Preventable Vaccine Company Product Type and Application
  8. 3.8 Global Pediatric Preventable Vaccine Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Pediatric Preventable Vaccine Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Pediatric Preventable Vaccine Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Pediatric Preventable Vaccine Market by Type
  1. 4.1 Pediatric Preventable Vaccine Type Introduction
  2. 4.1.1 Subunit Vaccines
  3. 4.1.2 Inactivated Vaccines
  4. 4.1.3 Live Vaccines
  5. 4.1.4 Viral Vector Vaccines
  6. 4.1.5 Mrna Vaccines
  7. 4.2 Global Pediatric Preventable Vaccine Sales Volume by Type
  8. 4.2.1 Global Pediatric Preventable Vaccine Sales Volume by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global Pediatric Preventable Vaccine Sales Volume by Type (2021-2032)
  10. 4.2.3 Global Pediatric Preventable Vaccine Sales Volume Share by Type (2021-2032)
  11. 4.3 Global Pediatric Preventable Vaccine Sales Value by Type
  12. 4.3.1 Global Pediatric Preventable Vaccine Sales Value by Type (2021 VS 2025 VS 2032)
  13. 4.3.2 Global Pediatric Preventable Vaccine Sales Value by Type (2021-2032)
  14. 4.3.3 Global Pediatric Preventable Vaccine Sales Value Share by Type (2021-2032)
5 Pediatric Preventable Vaccine Market by Application
  1. 5.1 Pediatric Preventable Vaccine Application Introduction
  2. 5.1.1 Bacterial Diseases
  3. 5.1.2 Virus Diseases
  4. 5.2 Global Pediatric Preventable Vaccine Sales Volume by Application
  5. 5.2.1 Global Pediatric Preventable Vaccine Sales Volume by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Pediatric Preventable Vaccine Sales Volume by Application (2021-2032)
  7. 5.2.3 Global Pediatric Preventable Vaccine Sales Volume Share by Application (2021-2032)
  8. 5.3 Global Pediatric Preventable Vaccine Sales Value by Application
  9. 5.3.1 Global Pediatric Preventable Vaccine Sales Value by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global Pediatric Preventable Vaccine Sales Value by Application (2021-2032)
  11. 5.3.3 Global Pediatric Preventable Vaccine Sales Value Share by Application (2021-2032)
6 Pediatric Preventable Vaccine Regional Sales and Value Analysis
  1. 6.1 Global Pediatric Preventable Vaccine Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Pediatric Preventable Vaccine Sales by Region (2021-2032)
  3. 6.2.1 Global Pediatric Preventable Vaccine Sales by Region: 2021-2026
  4. 6.2.2 Global Pediatric Preventable Vaccine Sales by Region (2027-2032)
  5. 6.3 Global Pediatric Preventable Vaccine Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Pediatric Preventable Vaccine Sales Value by Region (2021-2032)
  7. 6.4.1 Global Pediatric Preventable Vaccine Sales Value by Region: 2021-2026
  8. 6.4.2 Global Pediatric Preventable Vaccine Sales Value by Region (2027-2032)
  9. 6.5 Global Pediatric Preventable Vaccine Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Pediatric Preventable Vaccine Sales Value (2021-2032)
  12. 6.6.2 North America Pediatric Preventable Vaccine Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Pediatric Preventable Vaccine Sales Value (2021-2032)
  15. 6.7.2 Europe Pediatric Preventable Vaccine Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Pediatric Preventable Vaccine Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Pediatric Preventable Vaccine Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Pediatric Preventable Vaccine Sales Value (2021-2032)
  21. 6.9.2 South America Pediatric Preventable Vaccine Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Pediatric Preventable Vaccine Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Pediatric Preventable Vaccine Sales Value Share by Country, 2025 VS 2032
7 Pediatric Preventable Vaccine Country-level Sales and Value Analysis
  1. 7.1 Global Pediatric Preventable Vaccine Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Pediatric Preventable Vaccine Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Pediatric Preventable Vaccine Sales by Country (2021-2032)
  4. 7.3.1 Global Pediatric Preventable Vaccine Sales by Country (2021-2026)
  5. 7.3.2 Global Pediatric Preventable Vaccine Sales by Country (2027-2032)
  6. 7.4 Global Pediatric Preventable Vaccine Sales Value by Country (2021-2032)
  7. 7.4.1 Global Pediatric Preventable Vaccine Sales Value by Country (2021-2026)
  8. 7.4.2 Global Pediatric Preventable Vaccine Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Pediatric Preventable Vaccine Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Pediatric Preventable Vaccine Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Pediatric Preventable Vaccine Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Pediatric Preventable Vaccine Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Pediatric Preventable Vaccine Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Pediatric Preventable Vaccine Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Pediatric Preventable Vaccine Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Pediatric Preventable Vaccine Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Pediatric Preventable Vaccine Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Pediatric Preventable Vaccine Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Pediatric Preventable Vaccine Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Pediatric Preventable Vaccine Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Pediatric Preventable Vaccine Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Pediatric Preventable Vaccine Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Pediatric Preventable Vaccine Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Pediatric Preventable Vaccine Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Pediatric Preventable Vaccine Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Pediatric Preventable Vaccine Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Pediatric Preventable Vaccine Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Pediatric Preventable Vaccine Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Pediatric Preventable Vaccine Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Pediatric Preventable Vaccine Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Pediatric Preventable Vaccine Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Pediatric Preventable Vaccine Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Pediatric Preventable Vaccine Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Pediatric Preventable Vaccine Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Pediatric Preventable Vaccine Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Pediatric Preventable Vaccine Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Pediatric Preventable Vaccine Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Pediatric Preventable Vaccine Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Pediatric Preventable Vaccine Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Pediatric Preventable Vaccine Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Pediatric Preventable Vaccine Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Pediatric Preventable Vaccine Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Pediatric Preventable Vaccine Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Pediatric Preventable Vaccine Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Pediatric Preventable Vaccine Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Pediatric Preventable Vaccine Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Pediatric Preventable Vaccine Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Pediatric Preventable Vaccine Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Pediatric Preventable Vaccine Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Pediatric Preventable Vaccine Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Pediatric Preventable Vaccine Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Pediatric Preventable Vaccine Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Pediatric Preventable Vaccine Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Pediatric Preventable Vaccine Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Pediatric Preventable Vaccine Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Pediatric Preventable Vaccine Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Pediatric Preventable Vaccine Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Pediatric Preventable Vaccine Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Pediatric Preventable Vaccine Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Pediatric Preventable Vaccine Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Pediatric Preventable Vaccine Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Pediatric Preventable Vaccine Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Pediatric Preventable Vaccine Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Pediatric Preventable Vaccine Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Pediatric Preventable Vaccine Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Pediatric Preventable Vaccine Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Pediatric Preventable Vaccine Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Pediatric Preventable Vaccine Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Pediatric Preventable Vaccine Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Pediatric Preventable Vaccine Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Pediatric Preventable Vaccine Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Pediatric Preventable Vaccine Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Pediatric Preventable Vaccine Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Pediatric Preventable Vaccine Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Pediatric Preventable Vaccine Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Pediatric Preventable Vaccine Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Pediatric Preventable Vaccine Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Pediatric Preventable Vaccine Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Pediatric Preventable Vaccine Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Pediatric Preventable Vaccine Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Pediatric Preventable Vaccine Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Pediatric Preventable Vaccine Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Pediatric Preventable Vaccine Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Pediatric Preventable Vaccine Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Pediatric Preventable Vaccine Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Pediatric Preventable Vaccine Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Pediatric Preventable Vaccine Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Pediatric Preventable Vaccine Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Pediatric Preventable Vaccine Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Pediatric Preventable Vaccine Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Pediatric Preventable Vaccine Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Pediatric Preventable Vaccine Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Sanofi Pasteur
  2. 8.1.1 Sanofi Pasteur Company Information
  3. 8.1.2 Sanofi Pasteur Business Overview
  4. 8.1.3 Sanofi Pasteur Pediatric Preventable Vaccine Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Sanofi Pasteur Pediatric Preventable Vaccine Product Portfolio
  6. 8.1.5 Sanofi Pasteur Recent Developments
  7. 8.2 Johnson & Johnson (Janssen)
  8. 8.2.1 Johnson & Johnson (Janssen) Company Information
  9. 8.2.2 Johnson & Johnson (Janssen) Business Overview
  10. 8.2.3 Johnson & Johnson (Janssen) Pediatric Preventable Vaccine Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Johnson & Johnson (Janssen) Pediatric Preventable Vaccine Product Portfolio
  12. 8.2.5 Johnson & Johnson (Janssen) Recent Developments
  13. 8.3 Pfizer Inc.
  14. 8.3.1 Pfizer Inc. Company Information
  15. 8.3.2 Pfizer Inc. Business Overview
  16. 8.3.3 Pfizer Inc. Pediatric Preventable Vaccine Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Pfizer Inc. Pediatric Preventable Vaccine Product Portfolio
  18. 8.3.5 Pfizer Inc. Recent Developments
  19. 8.4 GlaxoSmithKline plc (GSK)
  20. 8.4.1 GlaxoSmithKline plc (GSK) Company Information
  21. 8.4.2 GlaxoSmithKline plc (GSK) Business Overview
  22. 8.4.3 GlaxoSmithKline plc (GSK) Pediatric Preventable Vaccine Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 GlaxoSmithKline plc (GSK) Pediatric Preventable Vaccine Product Portfolio
  24. 8.4.5 GlaxoSmithKline plc (GSK) Recent Developments
  25. 8.5 Sinovac Biotech
  26. 8.5.1 Sinovac Biotech Company Information
  27. 8.5.2 Sinovac Biotech Business Overview
  28. 8.5.3 Sinovac Biotech Pediatric Preventable Vaccine Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Sinovac Biotech Pediatric Preventable Vaccine Product Portfolio
  30. 8.5.5 Sinovac Biotech Recent Developments
  31. 8.6 Sinopharm Group Co.,
  32. 8.6.1 Sinopharm Group Co., Company Information
  33. 8.6.2 Sinopharm Group Co., Business Overview
  34. 8.6.3 Sinopharm Group Co., Pediatric Preventable Vaccine Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Sinopharm Group Co., Pediatric Preventable Vaccine Product Portfolio
  36. 8.6.5 Sinopharm Group Co., Recent Developments
  37. 8.7 Serum Institute of India Pvt.
  38. 8.7.1 Serum Institute of India Pvt. Company Information
  39. 8.7.2 Serum Institute of India Pvt. Business Overview
  40. 8.7.3 Serum Institute of India Pvt. Pediatric Preventable Vaccine Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Serum Institute of India Pvt. Pediatric Preventable Vaccine Product Portfolio
  42. 8.7.5 Serum Institute of India Pvt. Recent Developments
  43. 8.8 Novavax, Inc.
  44. 8.8.1 Novavax, Inc. Company Information
  45. 8.8.2 Novavax, Inc. Business Overview
  46. 8.8.3 Novavax, Inc. Pediatric Preventable Vaccine Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Novavax, Inc. Pediatric Preventable Vaccine Product Portfolio
  48. 8.8.5 Novavax, Inc. Recent Developments
  49. 8.9 Moderna, Inc.
  50. 8.9.1 Moderna, Inc. Company Information
  51. 8.9.2 Moderna, Inc. Business Overview
  52. 8.9.3 Moderna, Inc. Pediatric Preventable Vaccine Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Moderna, Inc. Pediatric Preventable Vaccine Product Portfolio
  54. 8.9.5 Moderna, Inc. Recent Developments
  55. 8.10 Merck & Co., Inc.
  56. 8.10.1 Merck & Co., Inc. Company Information
  57. 8.10.2 Merck & Co., Inc. Business Overview
  58. 8.10.3 Merck & Co., Inc. Pediatric Preventable Vaccine Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Merck & Co., Inc. Pediatric Preventable Vaccine Product Portfolio
  60. 8.10.5 Merck & Co., Inc. Recent Developments
  61. 8.11 Emergent BioSolutions Inc.
  62. 8.11.1 Emergent BioSolutions Inc. Company Information
  63. 8.11.2 Emergent BioSolutions Inc. Business Overview
  64. 8.11.3 Emergent BioSolutions Inc. Pediatric Preventable Vaccine Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Emergent BioSolutions Inc. Pediatric Preventable Vaccine Product Portfolio
  66. 8.11.5 Emergent BioSolutions Inc. Recent Developments
  67. 8.12 Daiichi Sankyo Company
  68. 8.12.1 Daiichi Sankyo Company Company Information
  69. 8.12.2 Daiichi Sankyo Company Business Overview
  70. 8.12.3 Daiichi Sankyo Company Pediatric Preventable Vaccine Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Daiichi Sankyo Company Pediatric Preventable Vaccine Product Portfolio
  72. 8.12.5 Daiichi Sankyo Company Recent Developments
  73. 8.13 CSL Limited (Seqirus)
  74. 8.13.1 CSL Limited (Seqirus) Company Information
  75. 8.13.2 CSL Limited (Seqirus) Business Overview
  76. 8.13.3 CSL Limited (Seqirus) Pediatric Preventable Vaccine Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 CSL Limited (Seqirus) Pediatric Preventable Vaccine Product Portfolio
  78. 8.13.5 CSL Limited (Seqirus) Recent Developments
  79. 8.14 Bharat Biotech International
  80. 8.14.1 Bharat Biotech International Company Information
  81. 8.14.2 Bharat Biotech International Business Overview
  82. 8.14.3 Bharat Biotech International Pediatric Preventable Vaccine Sales, Value and Gross Margin (2021-2026)
  83. 8.14.4 Bharat Biotech International Pediatric Preventable Vaccine Product Portfolio
  84. 8.14.5 Bharat Biotech International Recent Developments
  85. 8.15 AstraZeneca plc
  86. 8.15.1 AstraZeneca plc Company Information
  87. 8.15.2 AstraZeneca plc Business Overview
  88. 8.15.3 AstraZeneca plc Pediatric Preventable Vaccine Sales, Value and Gross Margin (2021-2026)
  89. 8.15.4 AstraZeneca plc Pediatric Preventable Vaccine Product Portfolio
  90. 8.15.5 AstraZeneca plc Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Pediatric Preventable Vaccine Value Chain Analysis
  2. 9.1.1 Pediatric Preventable Vaccine Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Pediatric Preventable Vaccine Sales Mode & Process
  6. 9.2 Pediatric Preventable Vaccine Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Pediatric Preventable Vaccine Distributors
  9. 9.2.3 Pediatric Preventable Vaccine Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst